Hemodynamic ,thyroid and immunomodulater effects of cannabinoid in rats.


Ismail Mustafa Maulood

Department of Biology, College of Science, Salahaddin University - Erbil, Kurdistan Region, Iraq,


Abstract

The aims of the present study are to investigate the cannabinoid effects on serum
monocyte chemoattractant protein-1 (MCP-1), Troponin-1 ,liver and renal test
parameters. The experimental rats were divided into three groups, the first group served
as a control, and the animals were injected with normal saline. In the second group,
animals were injected with cannabis (5 mg/kg, intraperitonial), while in the third group
animals were injected with cannabis (10 mg/kg). After the course of the experiment,
systolic blood pressure (SBP) tended to reduce significantly in the second dose of
cannabis administered rats. Serum nitric oxide (NO) level slightly increased in dose
dependent manner but it did not reach the level of significance. Serum level of
malondialdehyde (MDA), troponin-T, MCP-1 and serum total bilirubin were
significantly increased in the second dose of cannabis administration as compared to
control rats. Neither triiodothyronin (T3) nor tetraiodothyronin (T4) hormones had
statistically changed in cannabis group comparing with the control rats. Furthermore,
serum uric acid reduced in cannabis group as compared with control. In conclusions, for
the first time, our findings suggested that cannabis could affect immune system through
MCP-1 elevation. As well as, cannabis may affect cardiac and liver functions via
increasing troponin-T and bilirubin levels.

Key Words:
Blood
pressure,
Cannabinoid,
Cannabis, Thyroid,
MCP-1


References

[1] Hosking, R.D and Zajicek, J.P. ''Therapeutic potential of cannabis in pain medicine'', Br J Anaesth, Vol. (101), No. 1, pp. 59-68 (2008).

[2] Costa, B; Trovato, A.E; Comelli, F; Giagnoni. G. and Colleoni, M. ''The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain'', Eur J Pharmacol, Vol. (556), No. 1-3, pp. 75-83. (2007).

[3] Nagarkatti, P; Pandey, R; Rieder, S.A; Hegde, V.L. and Nagarkatti M. ''Cannabinoids as novel anti- inflammatory drugs'', Future Med Chem, Vol.( 1), No. 7, pp. 1333-49. (2009).

[4] Gebremedhin, D; Lange, A.R; Campbell, W.B; Hillard. C.J. and DR, H. ''Cannabinoid cb1 receptor of cat cerebral arterial muscle functions to inhibit l-type ca21 channel current'', The American Physiological Society, Vol. (99), pp. 0363-6135. (1999).

[5] Winsauer, P.J; Molina, P.E; Amedee, A.M; Filipeanu, C.M; McGoey, R.R. and Troxclair, D.A. '' Tolerance to chronic delta-9-tetrahydrocannabinol (Delta(9)-THC) in rhesus macaques infected with simian immunodeficiency virus'', Exp Clin Psychopharmacol, Vol. (19), No, 2, pp. 154-72. (2011).

[6] Leonard, E.J. and Yoshimura, T. "Human monocyte chemoattractant protein-1 (MCP-1)'', Immunol Today, Vol. (11), No. 3, pp. 97-101. (1990)

[7] O'Sullivan, S.E; Randall, M.D. and Gardiner, S.M. ''The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase'', J Pharmacol Exp Ther, Vol. (321) No. 2. pp. 663-72. (2007)

[8] Bonnet, U. ''Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function'' , Pharmacopsychiatry, Vol. (46), No. 1, pp. 35-6. (2013).

[9] Mach, F; Montecucco, F. and Steffens, S. ''Cannabinoid receptors in acute and chronic complications of atherosclerosis'', Br J Pharmacol, Vol. (153), No, 2, pp. 290-8. (2008).

[10] Gorelick, D.A; Goodwin, R.S; Schwilke, E. Schwope, D.M. Darwin, W.D. and Kelly, D.L. ''Tolerance to effects of high-dose oral delta9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers'', J Anal Toxicol, Vol. (37), No, 1, pp. 11-6. (2013)

[11] Schwope, D.M; Bosker, W.M; Ramaekers, J.G. Gorelick, D.A. and Huestis, M.A. ''Psychomotor performance, subjective and physiological effects and whole blood Delta(9)-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis'', J Anal Toxicol, Vol. (36), No. 6, 405-12. (2012).

[12] He, F.J; Marciniak, M. Carney, C. Markandu, N.D; Anand, V. and Fraser, W.D. ''Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives'', Hypertension, Vol. (55), No. 3, pp. 681-8. (2010).

[13] Akhtar, M.M; Iqbal, Y.H. and Kaski, J.C. ''Managing unstable angina and non-ST elevation MI'', Practitioner, Vol. (254), No. 1730, pp. 25-30. (2010)

[14] Fouad, A.A. and Jresat, I. ''Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats'', Eur J Pharmacol, Vol. (670), No. 1, pp. 216-23. (2011).

[15] Mandal, T.K. and Das, N.S. ''Effect of delta-9-tetrahydrocannabinol on altered antioxidative enzyme defense mechanisms and lipid peroxidation in mice testes'', Eur J Pharmacol, Vol. (607), No. 1-3, pp. 178-87. (2009)

[16] Fouad, A.A; Albuali, W.H; Al-Mulhim, A.S. and Jresat, I. ''Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity'', Environ Toxicol Pharmacol, Vol. (36), No. 2, pp. 347-57. (2013).

[17] Anna, P; Giorgio, M; Maria, A. C; Antonio. R., Maria, L. L. and Gessa, G.L. Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. European Journal of Endocrinology, Vol. (147), pp. 255–61. (2002)

[18] Yoshimura, T. and Leonard, E.J. ''Human monocyte chemoattractant protein-1: structure and function'', Cytokines, Vol.( 4), pp.131-52. (1992).

[19] Winsauer, P.J. and Molina, A. ''Tolerance to chronic delta-9-tetrahydrocannabinol (Delta(9)-THC) in rhesus macaques infected with simian immunodeficiency virus'', Exp Clin Psychopharmacol, Vol. (19), No, 2, pp. 154-72. (2011).

[20] Athanasiou, A; Clarke, A.B; Turner, A.E; Kumaran, N.M; Vakilpour, S and Smith, P.A. ''Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death'', Biochem Biophys Res Commun, Vol. (364), No. 1, pp. 131-7. (2007).

[21] Fujii, T; Yonemitsu, Y; Onimaru, M; Tanii, M; Nakano, T. and Egashira, K. ''Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway'', Arterioscler Thromb Vasc Biol, Vol. (26), No. 11, pp. 2483- 9. (2006).

[22] Toson, E. S. ''Impact of marijuana smoking on liver and sex hormones: Correlation with oxidative stress'', Nature and Science,Vol. (9), No. 12. (2011).

[23] Quraishi, R; Jain, R. Chatterjee, B. and Verma, A. ''Laboratory profiles of treatment-seeking subjects with concurrent dependence on cannabis and other substances: a comparative study'', Int J High Risk Behav Addict, Vol. (2), No. 3, pp. 107-11. (2013).

[24] Mallat, A. and Lotersztajn, S. ''Endocannabinoids and their role in fatty liver disease'', Dig Dis, Vol. (28), No. 1, pp. 261-6. (2010).

[25] Parfieniuk, A. and Flisiak, R. ''Role of cannabinoids in chronic liver diseases'' World J Gastroenterol, Vol. (14), No. 40, pp. 6109-14. (2008)

[26] Dunn, S. L; Wilkinson, J.M; Crawford, A. Le Maitre, C.L. and Bunning, R.A. ''Cannabinoid WIN-55,212- 2 mesylate inhibits interleukin-1beta induced matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human chondrocytes'', Osteoarthritis Cartilage, Vol. (22), No. 1, pp 133-44. (2014).